Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes

[1]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[2]  Benjamin Schubert,et al.  OptiType: precision HLA typing from next-generation sequencing data , 2014, Bioinform..

[3]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[4]  M. Irimia,et al.  Origin of spliceosomal introns and alternative splicing. , 2014, Cold Spring Harbor perspectives in biology.

[5]  Scott D. Brown,et al.  Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival , 2014, Genome research.

[6]  Eric S. Lander,et al.  A polygenic burden of rare disruptive mutations in schizophrenia , 2014, Nature.

[7]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[8]  M. Ni,et al.  Inference of high resolution HLA types using genome-wide RNA or DNA sequencing reads , 2014, BMC Genomics.

[9]  J. Harrow,et al.  Systematic evaluation of spliced alignment programs for RNA-seq data , 2013, Nature Methods.

[10]  Adam A. Margolin,et al.  Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas , 2013, Nature Genetics.

[11]  Xun Xu,et al.  An Integrated Tool to Study MHC Region: Accurate SNV Detection and HLA Genes Typing in Human MHC Region Using Targeted High-Throughput Sequencing , 2013, PloS one.

[12]  Mauricio O. Carneiro,et al.  The advantages of SMRT sequencing , 2013, Genome Biology.

[13]  H. Kim,et al.  HLA Haplotyping from RNA-seq Data Using Hierarchical Read Weighting , 2013, PloS one.

[14]  M. Zody,et al.  ATHLATES: accurate typing of human leukocyte antigen through exome sequencing , 2013, Nucleic acids research.

[15]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[16]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[17]  Helene Polin,et al.  Rapid, scalable and highly automated HLA genotyping using next-generation sequencing: a transition from research to diagnostics , 2013, BMC Genomics.

[18]  J. Castle,et al.  HLA typing from RNA-Seq sequence reads , 2012, Genome Medicine.

[19]  Richard A. Moore,et al.  Derivation of HLA types from shotgun sequence datasets , 2012, Genome Medicine.

[20]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[21]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[22]  S. Krishnakumar,et al.  High-throughput, high-fidelity HLA genotyping with deep sequencing , 2012, Proceedings of the National Academy of Sciences.

[23]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[24]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[25]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[26]  Vladimir Brusic,et al.  Ultra-high resolution HLA genotyping and allele discovery by highly multiplexed cDNA amplicon pyrosequencing , 2012, BMC Genomics.

[27]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[28]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[29]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[30]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[31]  Andrew R. Jones,et al.  Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..

[32]  N. Lennon,et al.  Next-generation sequencing for HLA typing of class I loci , 2011, BMC Genomics.

[33]  James Robinson,et al.  The IMGT/HLA database , 2008, Nucleic Acids Res..

[34]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[35]  J. Bubeník,et al.  MHC class I down-regulation: tumour escape from immune surveillance? (review). , 2004, International journal of oncology.

[36]  D. Speiser,et al.  α3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells1 , 2003, The Journal of Immunology.

[37]  D. Speiser,et al.  Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. , 2003, Journal of Immunology.

[38]  Vladimir Brusic,et al.  Prediction of promiscuous peptides that bind HLA class I molecules , 2002, Immunology and cell biology.

[39]  F. Garrido,et al.  A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line , 2001, Immunogenetics.

[40]  P. Stern,et al.  Multiple mechanisms underlie HLA dysregulation in cervical cancer. , 2000, Tissue antigens.

[41]  Gen Tamiya,et al.  Complete sequence and gene map of a human major histocompatibility complex , 1999 .

[42]  L. Fugger,et al.  Identification of 4 different alternatively spliced HLA-A transcripts. , 1999, Tissue antigens.

[43]  Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. , 1999, Nature.

[44]  M. Bunce,et al.  Molecular typing for the MHC with PCR-SSP. , 1999, Reviews in immunogenetics.

[45]  N. Greenspan,et al.  Class I MHC alpha 3 domain can function as an independent structural unit to bind CD8 alpha. , 1995, Molecular immunology.

[46]  D. Speiser,et al.  Oligotyping of HLA-A2, -A3, and -B44 subtypes. Detection of subtype incompatibilities between patients and their serologically matched unrelated bone marrow donors. , 1994, Human immunology.

[47]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[48]  P. Stastny,et al.  DNA typing for HLA class I alleles: I. Subsets of HLA-A2 and of -A28. , 1992, Human immunology.

[49]  P Parham,et al.  Structure, function, and diversity of class I major histocompatibility complex molecules. , 1990, Annual review of biochemistry.

[50]  A. Townsend,et al.  Antigen recognition by class I-restricted T lymphocytes. , 1989, Annual review of immunology.